Review article: Adverse effects caused by Anti-TNF therapy in adults with inflammatory bowel disease

Resumen

Crohn's Disease (CD) and Ulcerative Colitis (UC), the most common forms of Inflammatory Bowel Disease (IBD) have presented worldwide an increase in both incidence and prevalence in recent decades. Likewise, Latin America is not excluded from this epidemiological phenomenon. Biological therapy, specifically anti-TNF, was introduced for the first time in the USA in the year 98, this marked a before and after in the treatment of CD and CU since it allowed to change the natural evolution of the disease.  The
first anti-TNF molecule used was Infliximab, an IgG1 type chimeric monoclonal antibody, which is effective in inducing
and maintaining remission in CD # and CU Then fully humanized monoclonal antibodies such as Adalimumab was developed, which also proved to be effective in the treatment of both CD, and CU. As well as Golimumab and Certolizumab, which is a fab pegylated fragment of a humanized monoclonal antibody. Both are effective in inducing and maintaining remission in CU, and CD
respectively. However, the use of anti-TNFs may be associated with serious adverse effects, of which most of which are class effects.